Mast cells express functional CD30 ligand and are the predominant CD30L-positive cells in Hodgkin's disease.
about
Role of immune escape mechanisms in Hodgkin's lymphoma development and progression: a whole new world with therapeutic implicationsLymphoma: immune evasion strategiesMast cell infiltration correlates with poor prognosis in Hodgkin's lymphoma.Early and intermediate stage Hodgkin's lymphoma--report from the Swedish National Care Programme.Mast cells and eosinophils in invasive breast carcinoma.Abnormal interactions between perifollicular mast cells and CD8+ T-cells may contribute to the pathogenesis of alopecia areata.Mast cell survival and mediator secretion in response to hypoxiaMast cells and angiogenesis.Mast cell CD30 ligand is upregulated in cutaneous inflammation and mediates degranulation-independent chemokine secretion.Characterization of CD30/CD30L(+) Cells in Peripheral Blood and Synovial Fluid of Patients with Rheumatoid Arthritis.Hodgkin's lymphoma: molecular targets and novel treatment strategies.CD27-CD70 interactions in the pathogenesis of Waldenstrom macroglobulinemia.Biologic features of Hodgkin lymphoma and the development of biologic prognostic factors in Hodgkin lymphoma: tumor and microenvironment.CD30 on extracellular vesicles from malignant Hodgkin cells supports damaging of CD30 ligand-expressing bystander cells with Brentuximab-Vedotin, in vitro.The hydroxyflavone, fisetin, suppresses mast cell activation induced by interaction with activated T cell membranes.Aberrant expression of CD30 in aggressive systemic mastocytosis and mast cell leukemia: a differential diagnosis to consider in aggressive hematopoietic CD30-positive neoplasms.The role of T cells in the microenvironment of Hodgkin lymphoma.Microenvironmental interactions between endothelial and lymphoma cells: a role for the canonical WNT pathway in Hodgkin lymphoma.Mast cells promote the growth of Hodgkin's lymphoma cell tumor by modifying the tumor microenvironment that can be perturbed by bortezomib.Skin Immunity.Aberrant expression of CD30 in neoplastic mast cells in high-grade mastocytosis.Expression of mast cell tryptases in Hodgkin and Reed-Sternberg (HRS) cells.Increased serum levels of interleukin-9 correlate to negative prognostic factors in Hodgkin's lymphoma.The role of tumour-infiltrating eosinophils, mast cells and macrophages in Classical and Nodular Lymphocyte Predominant Hodgkin Lymphoma in children.Tumour-associated mast cells in classical Hodgkin's lymphoma: correlation with histological subtype, other tumour-infiltrating inflammatory cell subsets and outcome.Systemic Mastocytosis with Smoldering Multiple Myeloma: Report of a Case.Controversial role of mast cells in skin cancers.Predictors of histology, tissue eosinophilia and mast cell infiltration in Hodgkin's lymphoma--a population-based study.Brentuximab vedotin: clinical updates and practical guidance.CD30 expression by bone marrow mast cells from different diagnostic variants of systemic mastocytosis.Targeting Hodgkin and Reed-Sternberg Cells with an Inhibitor of Heat-Shock Protein 90: Molecular Pathways of Response and Potential Mechanisms of Resistance.The Microenvironment in Epstein-Barr Virus-Associated Malignancies.Pathobiology of hodgkin lymphomaVery high levels of soluble CD30 recognize the patients with classical Hodgkin's lymphoma retaining a very poor prognosis
P2860
Q27011510-6D8D2F67-8CE9-4E31-B478-E1F113F2BB42Q28080705-8A6CC19D-5CFE-4FF4-AFA2-BF4F041617BAQ33184751-321099CB-DAD0-4751-AE71-689342ED421FQ33186177-42BFD463-62D6-4E26-B598-D43FF00F7937Q33295438-AABF2F6A-5127-461F-B48B-88ACE68DF6B5Q33617937-7A1E4784-0EE5-4D50-9CAE-D008373304C6Q33680300-2215E903-C856-45A5-B58F-961934B54273Q34698798-A6D43D3A-9B49-413B-8101-509112E272A5Q35017864-1DD02D67-96DF-48F4-8D0C-A9861D056730Q35674652-8A251109-560E-43D8-A282-A717A0DE98DEQ36572545-D6E6FC0C-C368-44D7-9484-AA25B5C6F1CDQ37001989-AEFB92BB-5E67-4B4A-A2B8-E56F2D111D5AQ37271829-CB6D8049-62E8-42D6-B975-92FD0E5191E8Q37327528-45A5297F-CAC4-471F-B71F-2AFD0C5B8401Q37395933-40DF6532-FA32-4CB6-B715-8387416425EDQ37831903-68B72300-4424-475A-A1F2-F45CC9BE8780Q38576547-04BAFDEB-7447-4957-852D-0AB97E3965ECQ38751343-9C62DAD2-DE94-4644-A5E3-7E281E3FEA42Q39376791-5E710D1F-D272-4FD6-9B22-ECE68936FC92Q39379300-DDFF0940-9666-4C84-A7CE-7742E1B8030EQ39615506-85CFDF83-B041-4104-9495-956C0DF44425Q40049855-56716CA0-2A53-4599-B3BE-45833ACDA1D7Q40625623-464C4F50-5D1D-4C8B-82C9-8D663B99E23BQ40912853-A981C734-92CA-49D2-9E2A-427A0A8DA89DQ41745482-AEF17457-5ED4-467B-8A40-01E73B775E27Q42081445-F5584577-FB37-454C-A9AB-F0A148167C22Q42494705-8910EAE9-8C66-42A7-9E04-37B87ABB3670Q44227245-B2639ECC-0C88-4F77-9DD2-7F8125C7ABE3Q49282959-29E58353-70D3-474C-91FB-4C7E2869CB88Q50484927-78B3CE1B-66EC-4CC5-BB4D-BAC5A6DAFBA4Q52658034-3B0CD82C-2265-40C9-8C2E-E03FC335A2C4Q54236409-8336E696-D529-41A8-884F-6ED67B61307BQ56986903-0FE2DD5C-3096-4E2F-B2F0-1815A81CD0C5Q58924299-58F1DEBE-D366-476A-84DB-B3597DB32EB1
P2860
Mast cells express functional CD30 ligand and are the predominant CD30L-positive cells in Hodgkin's disease.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh
2001年學術文章
@zh-hant
name
Mast cells express functional ...... ve cells in Hodgkin's disease.
@en
type
label
Mast cells express functional ...... ve cells in Hodgkin's disease.
@en
prefLabel
Mast cells express functional ...... ve cells in Hodgkin's disease.
@en
P2093
P2860
P1476
Mast cells express functional ...... ive cells in Hodgkin's disease
@en
P2093
C Sundström
P2860
P304
P356
10.1046/J.1365-2141.2001.02977.X
P407
P577
2001-09-01T00:00:00Z